Decentralized science has turned out to be an initiative that is progressing at a humongous rate- which is also quite a massive upgrade for big pharma like Pfizer. This is now the first pharma company that has decided to vote on decentralized autonomous organization proposals for the German blockchain-based organization VitaDAO.
The collaboration between the pharma company and decentralized science is about to be a part of the latest fundraising of VitaDAO that was disclosed in the latter half of January from strategic members- which also includes L1 Digital, Shine Capital, and Pfizer Ventures- among other enthusiasts who have been in this field for quite some time.
Pfizer Has Collaborated With DeSci
The collaboration by Pfizer has raised $4.1 million which will fund the longevity research projects, which will also accelerate the spinout of the first biotech startups of VitaDAO– with a couple more in development for 2023. The awareness and community steward at VitaDAO, Alex Dobrin, also stated that big pharma has plans of bringing some scientists to participate with the community of researchers who are also a part of the blockchain organization in order to incubate a large part of the research.
DeSci has led to the creation of a thriving ecosystem where there are projects which range from decentralized biotech foundations like Pfizer to funding vehicles. Tuan Cao, the founder of Genomic DAO, stated that a large part of the major trends in this field will also include investment and research platforms, scientists, researchers, and crowdfunding for scientific research. The platform also aims at establishing a community to govern and drive Asian-focused precision medicine initiatives. The first subsidiary DAO has now been working on targeting awareness, stroke prevention, and research and development for ischemic strokes.
